i&i Bio, the newly estabilished investment fund powered by i&i Prague and EIF

It is our pleasure to announce the start of operations of i&i Biotech Fund (i&i Bio) in September 2021. This is a great success of i&i Prague team and it brings a new quality and a unique opportunity for early-phase deep-tech spin-offs in Czechia and rest of the Europe. i&i Bio focuses on unique technologies in the fields of Medtech, Diagnostics and Drug discovery. i&i Bio manages more than 45 million EUR and the fund is prepared to invest an average of 2 million EUR (more than 50 million CZK) in a specific project, but in exceptional cases the amount may grow to as much as 4.5 million EUR for a single project.

The fund will be joined by further investors in near future including CUIP, the daughter company of the Charles University in Prague.

Further details and press release could be found here!

(Photo: Michal Novotný)

About i&i Biotech Fund

The i&i Biotech Fund (i&i Bio) is an investment fund that has met the exacting criteria of the European Investment Fund (EIF) to become one of the more than 500 funds supported by the EIF. The fund was established with substantial involvement from i&i Prague, which in addition to financial backing will also be providing unique knowhow and expertise. The goal is to build on the results and experience of i&i Prague and increase the value of the fund’s assets by investing primarily in Czech and European biotechnology spinoffs. The fund makes significant contributions to the development and commercialization of original and quality projects in the areas of biotechnology and the natural sciences, namely those producing novel drugs, diagnostic methods, and medical devices.

i&i Bio is supported by lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. The Fund also benefits from the support by the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States.

More at: www.inibio.eu